Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Laquinimod · TV-5600, ABR-215062

Small molecule · developed by Teva Branded Pharmaceutical Products R&D

Phase 2 Most advanced trial (none active)

TEVA Developer

1 Registered trials

What is Laquinimod?

Laquinimod is an investigational small-molecule drug studied in Relapsing Remitting Multiple Sclerosis.

At a glance

Also known as: TV-5600, ABR-215062
Drug type: Small molecule
Therapy area: Neurology
Developer: Teva Branded Pharmaceutical Products R&D, Inc. (TEVA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 908SY76S4G

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00745615	Phase 2	Relapsing Remitting Multiple Sclerosis	Terminated	TEVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsing Remitting Multiple Sclerosis

More from Teva Branded Pharmaceutical Products R&D

Omacetaxine Mepesuccinate FDA approved TL011 Phase 1 TV-1106 Phase 2

Sources

ClinicalTrials.gov NCT00745615

Updated Oct 3, 2026. Something wrong or missing? Report it on the TEVA page.

Follow TEVA, the company behind Laquinimod

See TEVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TEVA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z